The newest wave of cancer therapies, including CAR-T cell therapy, bispecific antibodies and antibody-drug conjugates, is ...
Lean MASLD/MASH comprises a meaningful subset of patients, with lean MASH linked to higher all-cause mortality and liver events despite lower cardiometabolic comorbidity than obese disease. Adding ...
A post-2018 16.8% rise in Hispanic HIV incidence in anti-sanctuary counties temporally aligned with public charge expansion to Medicaid, consistent with deterrence from prevention, testing, and ...
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew ...
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid ...
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard ...
CPT under-specification for molecular diagnostics promotes widespread use of unclassified codes, undermining payer coverage ...
State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread ...
Fewer than one in five young people with first episode psychosis filled enough antipsychotic prescriptions to be considered ...
Tariffs on patented drugs broaden beyond Big Pharma, and exemptions, MFN deals and origin caps determine rates and potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results